These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 37735428)

  • 1. Evaluation of treatment patterns, healthcare resource utilization and cost of illness for sickle cell disease in Ghana: a private medical insurance claims database study.
    Marfo K; Dei-Adomakoh Y; Segbefia C; Dwomoh D; Edgal A; Ampah N; Ramachandrachar BC; Subramanyam K; Natarajan A; Egbujo O; Ataga KI
    BMC Health Serv Res; 2023 Sep; 23(1):1018. PubMed ID: 37735428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States.
    Udeze C; Evans KA; Yang Y; Lillehaugen T; Manjelievskaia J; Mujumdar U; Li N; Andemariam B
    Adv Ther; 2023 Aug; 40(8):3543-3558. PubMed ID: 37332020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payers.
    Shah NR; Bhor M; Latremouille-Viau D; Kumar Sharma V; Puckrein GA; Gagnon-Sanschagrin P; Khare A; Kumar Singh M; Serra E; Davidson M; Xu L; Guerin A
    J Med Econ; 2020 Nov; 23(11):1345-1355. PubMed ID: 32815766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical Resource Use and Costs of Treating Sickle Cell-related Vaso-occlusive Crisis Episodes: A Retrospective Claims Study.
    Shah N; Bhor M; Xie L; Paulose J; Yuce H
    J Health Econ Outcomes Res; 2020; 7(1):52-60. PubMed ID: 32685598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology and disease burden of sickle cell disease in France: A descriptive study based on a French nationwide claim database.
    Leleu H; Arlet JB; Habibi A; Etienne-Julan M; Khellaf M; Adjibi Y; Pirenne F; Pitel M; Granghaud A; Sinniah C; De Montalembert M; Galacteros F
    PLoS One; 2021; 16(7):e0253986. PubMed ID: 34242255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study.
    Shah N; Bhor M; Xie L; Halloway R; Arcona S; Paulose J; Yuce H
    Health Qual Life Outcomes; 2019 Oct; 17(1):155. PubMed ID: 31619251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sickle cell disease complications: Prevalence and resource utilization.
    Shah N; Bhor M; Xie L; Paulose J; Yuce H
    PLoS One; 2019; 14(7):e0214355. PubMed ID: 31276525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study.
    Campbell A; Cong Z; Agodoa I; Song X; Martinez DJ; Black D; Lew CR; Varker H; Chan C; Lanzkron S
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1121-1129. PubMed ID: 32597290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of adherence to hydroxyurea on health outcomes among patients with sickle cell disease.
    Kang HA; Barner JC; Lawson KA; Rascati K; Mignacca RC
    Am J Hematol; 2023 Jan; 98(1):90-101. PubMed ID: 36251408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of opioid use in sickle cell disease.
    Han J; Zhou J; Saraf SL; Gordeuk VR; Calip GS
    Pharmacoepidemiol Drug Saf; 2018 May; 27(5):479-486. PubMed ID: 28815799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost analysis of acute care resource utilization among individuals with sickle cell disease in a middle-income country.
    Lobo C; Moura P; Fidlarczyk D; Duran J; Barbosa R; Oliveira T; do Nascimento EM; Bhakta N; Hankins JS
    BMC Health Serv Res; 2022 Jan; 22(1):42. PubMed ID: 34998394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Healthcare Utilization in Adolescents with Sickle Cell Disease Prior to Transition to Adult Care: A Retrospective Study.
    Kanter J; Bhor M; Li X; Li FY; Paulose J
    J Health Econ Outcomes Res; 2019; 6(3):174-184. PubMed ID: 32685589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between Vaso-occlusive Crises and Opioid Prescriptions among Patients with Sickle Cell Disease: A Retrospective Claims-based Study.
    Kang HA; Barner JC; Richards KM; Bhor M; Paulose J; Kutlar A
    J Health Econ Outcomes Res; 2020; 7(1):94-101. PubMed ID: 32685602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global geographic differences in healthcare utilization for sickle cell disease pain crises in the CASiRe cohort.
    Strunk C; Tartaglione I; Piccone CM; Colombatti R; Andemariam B; Manwani D; Smith A; Haile H; Kim E; Wilson S; Asare EV; Rivers A; Farooq F; Urbonya R; Boruchov D; Boatemaa GD; Perrotta S; Ekem I; Sainati L; Rao S; Zempsky W; Sey F; Antwi-Boasiako C; Segbefia C; Inusa B; Campbell AD
    Blood Cells Mol Dis; 2021 Dec; 92():102612. PubMed ID: 34564050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Vaso-Occlusive Crises and Opioid Prescriptions Among Patients with Sickle Cell Disease: A Retrospective Claims-Based Study.
    Kang HA; Barner JC; Richards KM; Bhor M; Paulose J; Kutlar A
    J Health Econ Outcomes Res; 2020; 7(1):94-101. PubMed ID: 36873574
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevalence and cost of sickle cell disease in France: real-world analysis using data from the Echantillon Généraliste des Bénéficiaires.
    Beillat M; Durand-Zaleski I; Pirenne F; Bénard S; Chillotti L; Galacteros F
    Front Public Health; 2023; 11():1215605. PubMed ID: 37808997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An analysis of inpatient pediatric sickle cell disease: Incidence, costs, and outcomes.
    Bou-Maroun LM; Meta F; Hanba CJ; Campbell AD; Yanik GA
    Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28801954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity of the long-term economic burden of severe sickle cell disease: a 5-year longitudinal analysis.
    Gallagher ME; Chawla A; Brady BL; Badawy SM
    J Med Econ; 2022; 25(1):1140-1148. PubMed ID: 36222016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bridging the Access Gap for Comprehensive Sickle Cell Disease Management Across Sub-Saharan Africa: Learnings for Other Global Health Interventions?
    Hegemann L; Narasimhan V; Marfo K; Kuma-Aboagye P; Ofori-Acquah S; Odame I
    Ann Glob Health; 2023; 89(1):76. PubMed ID: 38025926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes and healthcare utilization in patients with sickle cell disease: a nationwide cohort study of Medicaid beneficiaries.
    Desai RJ; Mahesri M; Globe D; Mutebi A; Bohn R; Achebe M; Levin R; Schneeweiss S
    Ann Hematol; 2020 Nov; 99(11):2497-2505. PubMed ID: 32869184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.